{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:05:37Z","timestamp":1782443137507,"version":"3.54.5"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p>Augmented renal clearance (ARC, creatinine clearance\u00a0&gt;\u00a0130\u00a0mL\/minute) makes difficult achievement of effective concentrations of renally cleared antibiotics in critically ill patients. This study examined the synergistic killing and resistance suppression for meropenem\u2010ciprofloxacin combination dosage regimens against <jats:italic>Pseudomonas aeruginosa<\/jats:italic> isolates within the context of ARC. Clinically relevant meropenem and ciprofloxacin concentrations, alone and in combinations, were studied against three clinical isolates with a range of susceptibilities to each of the antibiotics. Isolate Pa1280 was susceptible to both meropenem and ciprofloxacin, Pa1284 had intermediate susceptibility to meropenem and was susceptible to ciprofloxacin, and CR380 was resistant to meropenem and had intermediate susceptibility to ciprofloxacin. Initially, isolates were studied in 72\u2010hour static\u2010concentration time\u2010kill (SCTK) studies. Subsequently, the pharmacokinetic profiles expected in patients with ARC receiving dosage regimens, including at the highest approved daily doses (meropenem 6\u00a0g daily divided and administered as 0.5\u2010hour infusions every 8\u00a0hours, or as a continuous infusion; ciprofloxacin 0.4\u00a0g as 1\u2010hour infusions every 8\u00a0hours), were examined in a dynamic hollow\u2010fiber infection model (HFIM) over 7\u201310\u00a0days. In both SCTK and HFIM, combination regimens were generally synergistic and suppressed growth of less\u2010susceptible subpopulations, these effects being smaller for isolate CR380. The time\u2010courses of total and less\u2010susceptible bacterial populations in the HFIM were well\u2010described by mechanism\u2010based models, which enabled conduct of Monte Carlo simulations to predict likely effectiveness of approved dosage regimens at different creatinine clearances. Optimized meropenem\u2010ciprofloxacin combination dosage regimens may be a viable consideration for <jats:italic>P.\u00a0aeruginosa<\/jats:italic> infections in critically ill patients with ARC.<\/jats:p>","DOI":"10.1002\/cpt.2191","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T13:07:08Z","timestamp":1612703228000},"page":"1104-1115","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of Meropenem\u2010Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance"],"prefix":"10.1111","volume":"109","author":[{"given":"Akosua A.","family":"Agyeman","sequence":"first","affiliation":[{"name":"Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Tait","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip J.","family":"Bergen","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Wallis","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research Royal Brisbane and Women\u2019s Hospital Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen B.","family":"Bulitta","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research College of Pharmacy University of Florida Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research Royal Brisbane and Women\u2019s Hospital Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research Royal Brisbane and Women\u2019s Hospital Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[{"name":"Drug Delivery, Disposition, and Dynamics Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research Royal Brisbane and Women\u2019s Hospital Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety Monash Institute of Pharmaceutical Sciences Monash University Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.10.008"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000510"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000029"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.06.002"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.05.010"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000346"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa267"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw153"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02642-16"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-18"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01679-19"},{"key":"e_1_2_10_12_1","article-title":"Beta lactam antibiotic monotherapy versus beta lactam\u2010aminoglycoside antibiotic combination therapy for sepsis","volume":"2014","author":"Paul M.","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00065-10"},{"key":"e_1_2_10_14_1","article-title":"Meropenem combined with ciprofloxacin combats hypermutable pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients","volume":"62","author":"Rees V.E.","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_10_15_1","unstructured":"Clinical and Laboratory Standards Institute M100\u2010ED30:2020.Performance standards for antimicrobial susceptibility testing<http:\/\/em100.edaptivedocs.net\/Login.aspx?_ga=2.225350042.1056870820.1519776796\u2010996775173.1462755813> (2020). Accessed October 27 2020."},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02534-17","article-title":"\u03b2\u2010lactam dosage regimens in septic patients with augmented renal clearance","volume":"62","author":"Jacobs A.","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp139"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1065"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr220"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05664-11"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv165"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu027"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.2.227"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2013.0229"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00469-20"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00489-08"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00092-13"},{"key":"e_1_2_10_28_1","unstructured":"Intravenous meropenem summary of product characteristics<https:\/\/www.medicines.org.uk\/emc\/medicine\/11215#gref> (2019). Accessed October 27 2020."},{"key":"e_1_2_10_29_1","unstructured":"Intravenous ciprofloxacin summary of product characteristics<https:\/\/www.medicines.org.uk\/emc\/product\/419\/smpc#gref> (2020). Accessed October 27 2020."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.4920-4927.2005"},{"key":"e_1_2_10_32_1","first-page":"429","article-title":"\u03b2\u2010Lactam pharmacodynamics in Gram\u2010negative bloodstream infections in the critically ill","volume":"75","author":"Wong G.","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04337.x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06389-11"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2012.05715.x"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-013-3187-2"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70036-2"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky314"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4226-4233.2004"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01437-05"},{"key":"e_1_2_10_41_1","first-page":"497","article-title":"Elevated \u03b2\u2010lactam concentrations associated with neurological deterioration in ICU septic patients","volume":"81","author":"Beumier M.","year":"2015","journal-title":"Minerva Anestesiol."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03991.x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004782"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00192-9"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00689-07"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu603"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2191","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:38:21Z","timestamp":1699364301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/cpt.2191"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2191","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"2020-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}